ARCTURUS THERAPEUTICS HOLDINGS INC. Increase (Decrease) in Accounts Receivable
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Increase (Decrease) in Accounts Receivable of -$3.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $470.00K, a 82.14% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$4.22M, a 139.83% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$2.39M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$9.25M, a 251.34% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2025 was $1.59M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2024 was -$28.09M, a 195.87% decline from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2023 was $29.30M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2022 was -$603.00K, a 148.55% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.75M 10-Q · filed 2026-08-06 | -$6.14M derived: sum of 3 quarters · filed 2026-08-06 | -$15.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.22M 10-Q · filed 2026-05-07 | -$6.61M derived: sum of 2 quarters · filed 2026-05-07 | -$15.86M derived: sum of 3 quarters · filed 2026-05-07 | -$13.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$11.64M derived: sum of 2 quarters · filed 2026-03-03 | -$9.01M derived: sum of 3 quarters · filed 2026-08-06 | $1.59M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.62M derived: sum of 2 quarters · filed 2026-08-06 | $3.98M 10-Q · filed 2025-11-12 | -$22.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.23M 10-Q · filed 2026-08-06 | -$12.99M derived: sum of 3 quarters · filed 2026-08-06 | -$6.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.60M 10-Q · filed 2026-05-07 | -$15.63M derived: sum of 2 quarters · filed 2026-05-07 | -$9.51M derived: sum of 3 quarters · filed 2026-05-07 | -$12.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$20.11M derived: sum of 2 quarters · filed 2026-03-03 | -$23.08M derived: sum of 3 quarters · filed 2026-03-03 | -$28.09M 10-K · filed 2026-03-03 |
| 2024-09-30 | $6.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.14M derived: sum of 2 quarters · filed 2025-11-12 | -$1.86M 10-Q · filed 2025-11-12 | -$8.02M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$7.98M 10-Q · filed 2025-08-11 | -$14.13M derived: sum of 3 quarters · filed 2026-03-03 | $21.29M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$5.01M 10-Q · filed 2025-05-12 | -$11.16M derived: sum of 2 quarters · filed 2026-03-03 | $24.26M derived: sum of 3 quarters · filed 2026-03-03 | -$65.43M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $29.27M derived: sum of 2 quarters · filed 2026-03-03 | -$60.42M derived: sum of 3 quarters · filed 2026-03-03 | $29.30M 10-K · filed 2026-03-03 |
| 2023-09-30 | $35.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$54.26M derived: sum of 2 quarters · filed 2024-11-07 | $35.46M 10-Q · filed 2024-11-07 | $36.18M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$89.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $35.00K 10-Q · filed 2024-08-05 | $755.00K derived: sum of 3 quarters · filed 2025-03-06 | $552.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $89.72M 10-Q · filed 2024-05-08 | $90.44M derived: sum of 2 quarters · filed 2025-03-06 | $90.24M derived: sum of 3 quarters · filed 2025-03-06 | $88.79M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $720.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $517.00K derived: sum of 2 quarters · filed 2025-03-06 | -$927.00K derived: sum of 3 quarters · filed 2025-03-06 | -$603.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | -$203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.65M derived: sum of 2 quarters · filed 2023-11-14 | -$1.32M 10-Q · filed 2023-11-14 | $29.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.12M 10-Q · filed 2023-08-07 | $232.00K derived: sum of 3 quarters · filed 2024-03-14 | $84.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $324.00K 10-Q · filed 2023-05-09 | $1.68M derived: sum of 2 quarters · filed 2024-03-14 | $1.53M derived: sum of 3 quarters · filed 2024-03-14 | $1.68M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.20M derived: sum of 2 quarters · filed 2024-03-14 | $1.36M derived: sum of 3 quarters · filed 2024-03-14 | $1.24M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $8.00K derived: sum of 2 quarters · filed 2022-11-09 | -$110.00K 10-Q · filed 2022-11-09 | -$432.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $38.00K 10-Q · filed 2022-08-09 | -$284.00K derived: sum of 3 quarters · filed 2022-08-09 | -$666.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$118.00K 10-Q · filed 2022-05-09 | -$440.00K derived: sum of 2 quarters · filed 2022-05-09 | -$822.00K derived: sum of 3 quarters · filed 2022-05-09 | -$344.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$704.00K derived: sum of 2 quarters · filed 2022-03-01 | -$226.00K derived: sum of 3 quarters · filed 2022-03-01 | -$54.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | -$382.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $96.00K derived: sum of 2 quarters · filed 2021-11-09 | $268.00K 10-Q · filed 2021-11-09 | -$178.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $478.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $650.00K 10-Q · filed 2021-08-10 | $204.00K derived: sum of 3 quarters · filed 2022-03-01 | -$2.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $172.00K 10-Q · filed 2021-05-10 | -$274.00K derived: sum of 2 quarters · filed 2022-03-01 | -$3.47M derived: sum of 3 quarters · filed 2022-03-01 | -$2.11M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.64M derived: sum of 2 quarters · filed 2022-03-01 | -$2.28M derived: sum of 3 quarters · filed 2022-03-01 | -$2.30M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$1.83M derived: sum of 2 quarters · filed 2020-11-09 | -$1.86M 10-Q · filed 2020-11-09 | $1.50M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.34M 10-Q · filed 2020-08-10 | $4.69M derived: sum of 3 quarters · filed 2021-03-01 | $4.45M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$24.00K 10-Q · filed 2020-05-08 | $3.33M derived: sum of 2 quarters · filed 2021-03-01 | $3.09M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.11M derived: sum of 2 quarters · filed 2021-03-01 | $4.00M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $643.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $891.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |